NTRK1 and cancer: Several TKIs now have demonstrated activity across cancer types, so called “agnostic” indications, including the TRK inhibitor larotrectinib, the TRK/ROS1 inhibitor entrectinib, and the RET inhibitors selpercatinib and pralsetinib (5, 6, 32–34).